Zacks Investment Research
30 Jul 2026, 23:06 UTC · 11w ago
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
Impact · against what's priced in
Myriad Genetics faces significant downward pressure following a massive earnings miss and declining year-over-year revenue. The combination of a -733.33% earnings surprise and a 7.12% revenue miss indicates a deterioration in fundamental performance that the market had not fully accounted for.
- MYGN−0.70
No priced-in read yet
- In context
The company reported a quarterly loss of $0.25 per share against an expected $0.03 loss, alongside revenues of $190.7 million which fell short of estimates by 7.12% and declined from $213.1 million last year.
Read from the article alone
Top 1 mover · tap to explore
